Aims/hypothesis AMP-activated protein kinase (AMPK) is an evolutionarily conserved enzyme and a target of glucose-lowering agents, including metformin. However, the precise role or roles of the enzyme in controlling insulin secretion remain uncertain. Methods The catalytic α1 and α2 subunits of AMPK were ablated selectively in mouse pancreatic beta cells and hypothalamic neurons by breeding Ampkα1 [also known as Prkaa1]-knockout mice, bearing floxed Ampkα2 [also known as Prkaa2] alleles (Ampkα1 −/− ,α2 fl/fl ,), with mice expressing Cre recombinase under the rat insulin promoter (RIP2). RIP2 was used to express constitutively activated AMPK selectively in beta cells in transgenic mice. Food intake, body weight and urinary catecholamines were measured using metabolic cages. Glucose and insulin tolerance were determined after intraperitoneal injection. Beta cell mass and morphology were analysed by optical projection tomography and confocal immunofluorescence microscopy, respectively. Granule docking, insulin secretion, membrane potential and intracellular free Ca 2+ were measured with standard techniques.
Introduction
AMP-activated protein kinase (AMPK) is an evolutionarily conserved fuel-sensitive protein kinase implicated in the control of glucose homeostasis and playing roles in insulinsensitive tissues [1] [2] [3] and in the pancreatic beta cell [4] [5] [6] [7] . While the stimulation of AMPK activity in muscle and liver is now seen as a likely mechanism through which glucoselowering agents, including metformin and thiazolidinediones, act to improve insulin sensitivity [8] , the long-term effects of these agents on pancreatic beta cell survival and insulin release are less clear [7] .
Mammalian AMPK is a trimeric protein comprising a catalytic α-subunit, encoded by one of two separate genes (Ampkα1 [also known as Prkaa1] and Ampkα2 [also known as Prkaa2]), a scaffold β-(β1 or β2) subunit and a regulatory γ-subunit (γ1, γ2 or γ3) [9, 10] . The existence of two separate AMPKα subunit genes has so far hindered investigations of the role AMPK activity plays in controlling glucose homeostasis in mammals, since the unconditional deletion of both isoforms leads to early embryonic lethality in mice [11] . By contrast, animals with global inactivation of the AMPKα1 isoform do not display significant metabolic abnormalities [11, 12] . Deletion of the Ampkα2 gene leads to insulin resistance and glucose intolerance, in part due to increased parasympathetic tone [13] . Whereas insulin secretion was normal in islets isolated from whole-body Ampkα2 knockout mice, insulin release in vivo appeared to be diminished when measured at a single time point during oral glucose tolerance tests. However, no measurements were made during intraperitoneal glucose tolerance tests, where the complicating effects of potentially altered incretin release could be excluded. Importantly, since complexes containing the AMPKα1 isoform are substantially (>tenfold) more abundant in beta cell lines than AMPKα2 complexes [5] , increases in expression of the former may also, in part, have compensated for the loss of AMPKα2.
The cell-permeant AMPK activator, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), diminishes glucose-stimulated insulin secretion from clonal beta cells and islets [4, 6] , an effect mimicked by the biguanide metformin [14] or by the expression of a constitutively active form of AMPK [6] . Moreover, overexpression of constitutively active AMPK diminished the performance of islets transplanted into streptozotocin-induced diabetic mice [15] . These actions may be due in part to blockade of secretory granule transport to the cell surface [16] as a result of kinesin-1 light chain phosphorylation [17] . In addition, AMPK activation decreases beta cell viability [18, 19] possibly by phosphorylating the cell cycle regulator, p53 [20] . By contrast, inhibition of AMPK activity with dominant-negative forms of the enzyme tends to increase insulin secretion at low glucose concentrations [6] without affecting release at elevated glucose concentrations [21] , a finding that is consistent with inactivation of the enzyme as a result of AMP depletion under these conditions. AMPK is also thought to play an important role in the central control of feeding and glucose homeostasis. Thus, forced changes in AMPK in the ventromedial hypothalamus achieved by stereotactic injection of viral vectors led to marked changes in food intake and body weight [22] and in hypoglycaemia sensing [23, 24] . Moreover, the deletion of Ampkα2 in neurons expressing pro-opiomelanocortin or agouti-related peptide leads respectively to increased or decreased food intake in mice [25] . Finally, manipulation of AMPK activity ex vivo was found to affect glucose-induced changes in the electrical activity of Ca 2+ transients in isolated agouti-related peptide (glucose-inhibited), but not in pro-opiomelanocortin (glucose-responsive) neurons in culture [26, 27] .
We have previously demonstrated distinct roles in the pancreatic beta cell for AMPK complexes containing differing catalytic subunits [5] . Thus, the α2 subunit, which displayed substantial nuclear localisation [4, 5] , was implicated in control of gene expression, whereas α1-containing complexes, whose total activity exceeded that of α2-containing complexes by five to ten fold [5] , were almost exclusively cytosolic. The role of the latter remains unclear, but may include regulation of plasma membrane ion channels, as proposed in oxygen-sensing cells in the carotid body [28] .
To assess the role of AMPK in insulin-expressing cells, we generated trigenic mice that were globally inactivated for Ampkα1 and had Ampkα2 deleted selectively in pancreatic beta cells and in a small population of hypothalamic neurons, using the rat insulin promoter (RIP)2 [29] and transgenic mice expressing activated AMPK selectively in beta cells. Using these models we highlight multiple novel mechanisms through which AMPK controls insulin production and glucose homeostasis in mammals. 312 .T172D (CA) or AMPKα2.D157A (DN) cDNA, and an SV40 poly (A) cassette was excised with BssHII and microinjected into the male pronucleus of fertilised C57BL/6 oocytes. The injected zygotes were re-implanted into pseudo-pregnant female C57BL/6 mice (GenOway, Lyon Cedex, France). We obtained three AMPK.CA (named C1, C2 and C10) and two AMPK.DN (D1 and D2) founder mice that stably transferred the corresponding transgenes to their offspring. Founder mice were crossed with wild-type C57BL/6 mice to achieve F1 generation. Distributions of genotypes in the offspring followed a Mendelian pattern. All AMPK transgenic mice were kept heterozygous. F3 and later generations, and their littermate wild-type controls were used for experiments. All lines were maintained on a pure C57BL/6 background.
Methods

Generation of mutant mice lacking
Mouse maintenance and diet
Mice were housed two to five animals per cage in a pathogen-free facility with 12 h light/dark cycle and had free access to standard mouse chow diet or a high-fat diet (60% [wt/wt] fat content; Research Diet, New Brunswick, NJ, USA). As indicated, 6-week-old mice were transferred to a high-fat diet for a maximum of 18 weeks. All in vivo procedures described here were performed at the Imperial College Central Biomedical Service and approved by the UK Home Office Animals Scientific Procedures Act, 1986.
Body weight and food intake
Fed mouse weights were monitored weekly after 6 weeks of age. Food intake was measured daily for three consecutive days using a metabolic cage.
In vivo physiological studies
Intraperitoneal glucose tolerance test Mice fasted for 15 h (water allowed) were intraperitoneally injected with 1 g glucose/kg mouse weight. Blood from the tail vein was obtained at 0, 15, 30, 60, 90 and 120 min after injection. Blood glucose levels were measured with an automatic glucometer (Accuchek; Roche, Burgess Hill, UK). To study the effect of α-adrenergic antagonist on glucose tolerance, mice were intraperitoneally injected with 10 mg/kg mouse weight phentolamine 30 min before glucose challenge.
Plasma insulin measurement Mice fasted for 15 h were intraperitoneally injected with 3 g glucose/kg mouse weight. Blood from mice tail veins was collected into a heparin coated tube (Sarstedt, Beaumont Leys, UK) at 0, 15 and 30 min after injection. Plasma was separated by centrifuging the blood at 2,000 g for 5 min. Plasma insulin levels were measured using an ultrasensitive mouse insulin ELISA kit (Mercodia, Uppsala, Sweden). Normal fed plasma insulin levels were and (f) plasma insulin response, after intraperitoneal (IP) glucose injection, and (g) whole-body insulin sensitivity after IP insulin injection. Triangles, βAMPKdKO; circles, Het. Data are expressed as means ± SEM; n=7-9; *p<0.05, **p<0.01, ***p<0.001 measured from blood collected from tail veins of 12-week-old mice between 10:00 and 11:00 hours.
Insulin tolerance test Bovine insulin (0.75 U/kg; Sigma, Dorset, UK) was intraperitoneally injected into fed mice between 13:00 and 14:00 hours. Blood glucose levels were measured at 0, 15, 30 and 60 min after injection.
Urine collection and catecholamine measurement
Daily urine collection from each mouse for a period of 3 days was performed using metabolic cages. Catecholamine levels in urine were determined by reverse-phase HPLC.
Other methods Details of islet isolation and insulin secretion, electron microscopy, electrophysiology, optical projection tomography, Ca 2+ imaging, RNA extraction and RT-PCR, AMPK assay, antibodies and immunohistochemistry are provided in Electronic supplementary material (ESM 1).
Statistical analysis
Data are expressed as means ± SEM. Significance was tested by two samples unpaired or paired Student's t test using Excel, or by ANOVA using Graphpad 4.0. A value of p<0.05 was considered significant.
Results
βAMPKdKO mice have normal body weight but are hyperglycaemic mRNAs encoding Ampkα1 and -α2 subunits were present in highly purified [32, 33] wild-type mouse beta cells (ESM Fig. 1 ). Ampkα1 mRNA was ∼15-fold more abundant than that encoding the α2 subunit, in line with previous AMPK activity measurements in clonal beta cells [5] and with the distinct roles of each isoform in these cells [5] . Since mice deleted globally for either subunit display essentially normal insulin release in vitro [13] , we generated trigenic mice inactivated for AMPKα1 and α2 subunits selectively in beta cells and in a small population of hypothalamic neurons. Mice globally inactivated for Ampkα1 [11] were first crossed with animals bearing floxed Ampkα2 gene alleles (Fig. 1a) . Crossing with RIP2.Cre mice [29] led to a selective loss of the catalytic domain of the Ampkα2 subunit (aa189-260) from islets and hypothalamus (Fig. 1a, b) . Consistent with the abundant expression in islets of the Cre transgene (Fig. 1c) and selective deletion of the two catalytic subunits from beta cells [34] , the crossing of Ampkα2 floxed and RIP2.Cre mice resulted in a decrease in islet Ampkα2 mRNA of 60 to 70% (Fig. 1d) . Assessed at low glucose concentrations to near-maximally stimulate the enzyme [14] , total islet AMPK activity was decreased by 93% in Ampkα1 −/− vs
.Cre − in each case) mice and by 95% in βAMPKdKO mice vs Ampkα1 +/− (Fig. 1e) . Male βAMPKdKO mice displayed entirely normal growth and normal food intake (Fig. 1f, g ), while females had a small reduction in body weight up to 10 weeks of age (ESM Fig. 2a ). Assessed at 3 (Fig. 2a, c ) and 6 months (not shown) of age, βAMPKdKO mice of either sex, but not mice deleted for either Ampkα1 [12] or -α2 (ESM Fig. 3 ) alone, displayed markedly elevated plasma glucose and decreased plasma insulin levels ( Fig. 2a-d, ESM Fig. 3) . Correspondingly, double knockout mice displayed abnormal glucose tolerance and insulin release in vivo, despite increased insulin sensitivity (Fig. 2e-g ,α2 fl/+ ,Cre + control mice (not shown). Since mice with global homozygous deletion of Ampkα2 display abnormal insulin secretion in vivo and elevated catecholamine levels [13] , we determined whether the latter variable may contribute to abnormal insulin secretion in Fig. 3 Role of catecholamines in the control of insulin secretion in βAMPKdKO mice. a Urinary noradrenaline (Noradren, norepinephrine), adrenaline (Adren, epinephrine) and dopamine levels. Black bars, βAMPKdKO; white bars, heterozygous. b Glucose tolerance of βAMPKdKO (triangles) or heterozygous control (white circles) mice 30 min. after IP phentolamine injection. Male mice aged 12-14 weeks were used. Data are expressed as means ± SEM; n=6-8; *p<0.05 βAMPKdKO mice. We detected no alterations in the levels of urinary catecholamines (Fig. 3a) , indicating that the above was not the case. Moreover, abnormal glucose tolerance was still observed, albeit diminished in extent, in the presence of the α-adrenoreceptor blocker, phentolamine (Fig. 3b) [35] .
βAMPKdKO mice have normal beta cell mass but smaller beta cells and islets Changes in relative beta cell mass, which might have explained the marked decrease in insulin release in βAMPKdKO animals, were not observed as assessed by optical projection tomography of whole pancreases [36] ( Fig. 4a-d ; ESM video clips 1 and 2) or through analysis of pancreatic slices (ESM Fig. 4) . However, the distribution of islet sizes between heterozygous and βAMPKdKO animals, as assessed by optical projection tomography, revealed a significant ∼40% decrease in the average volume of individual islets (Fig. 4b, c, e) .
By contrast, no differences were apparent in the ratio of alpha to beta cells within individual islets or in the relative disposition of the two cell types (Fig. 5a) . Similarly, despite proposed roles for AMPK and the upstream kinase liver kinase B1 (LKB1) in the control of beta cell polarity [37] [38] [39] (Fig. 5c) , and microfilament and microtubule structure were unchanged in islets from βAMPKdKO mice (not shown).
AMPK is a known regulator of the mechanistic target of rapamycin (mTOR) complex, acting to phosphorylate the mTORC1 components Raptor and the upstream regulator tuberous sclerosis complex-2 [40] . Since mTOR is involved in the regulation of cell size [41] , we assessed the size of individual beta cells, using anti-E-cadherin (Fig. 5d, e) or anti-GLUT2 (not shown) antibodies to label the plasma membrane. This revealed an ∼18% decrease in the average area of beta cells, corresponding to a decrease in volume of ∼36%, closely in line with the reduction in average islet size. However, no changes in the phosphorylation state of the downstream targets of mTOR, ribosomal S6 subunits, were detected (not shown), arguing against changes in the activity of the latter pathway being responsible for the decrease in beta cell volume. Unexpectedly, beta cell proliferation was also substantially (more than twofold) increased, as assessed by Ki67 staining (Fig. 5f, g ). No changes in the low level of apoptosis could be detected by caspase-3 or in situ TUNEL staining (not shown), possibly reflecting rapid clearance of apoptotic cells.
Glucose-induced insulin secretion is enhanced in islets from βAMPKdKO mice but beta cell electrical activity and intracellular free Ca 2+ changes are normal
The above analyses revealed a profound compromise in the capacity of an unchanged mass of morphologically normal beta cells to release insulin in vivo. To determine whether this reflected a change in the intrinsic properties of beta cells, we next analysed insulin release from isolated islets and glucose-sensing by dissociated beta cells. In contrast to what was observed in vivo, islets from βAMPKdKO mice displayed significantly elevated rates of glucose-stimulated insulin release compared with control (heterozygote) islets (Fig. 6a ), arguing for a restraining effect of AMPK on hormone release. Unexpectedly, the previously described inhibitory effects of AMPK activation with the AMPK activator and AMP analogue AICAR [4, 6] were still preserved in βAMPKdKO mouse islets, indicating that the effects of this activator were largely independent of AMPK. To determine whether beta cells from βAMPKdKO mouse islets show altered glucose sensing, as observed after LKB1 deletion (G. Sun, A. Tarasov, J. McGinty, P.M. French, A. McDonald, I. Leclerc and G. Rutter, unpublished results), we used electrophysiological approaches. While glucose-induced changes in the conductance of ATP-sensitive K + channels revealed lower conductance of these channels at low (3 mmol/l) but not elevated (16.7 mmol/) glucose in βAMPKdKO beta cells compared with heterozygous controls, this did not translate into a difference in membrane potential changes (Fig. 6b, c) . Likewise, no differences were apparent in the extent of glucose or depolarisation-(KCl-) induced increases in intracellular free Ca 2+ ions in heterozygous compared with βAMPKdKO beta cells (Fig. 6d-g ). Correspondingly, again in contrast to the impact of LKB1 deletion (G. Sun, A. Tarasov, J. McGinty, P.M. French, A. McDonald, I. Leclerc and G. Rutter, unpublished results), no differences were observed in the levels or plasma membrane association of the liver/beta cell glucose transporter Glut2 (Fig. 6h) [42] . By contrast, the number of morphologically docked granules was significantly increased in βAMPKdKO beta cells (Fig. 6i, j) .
We next determined whether AMPK present in beta cells and RIP2.Cre neurons contribute to the deleterious effects of a high-fat diet on insulin release and glucose homeostasis [43] . No differences in body weight gain were apparent between heterozygous and βAMPKdKO mice maintained on high-fat diet (Fig. 7a) . However, after 6 weeks on highfat diet, which is sufficient to cause profound abnormalities in glucose-induced insulin secretion in C57BL/6 mice [43] , the differences in glycaemia observed between heterozygote and βAMPKdKO mice observed on a normal diet (Fig. 2a, b, e) were abolished (Fig. 7b) . This change reflected a more dramatic increase in glucose levels in the heterozygous mice on high-fat diet than in those on normal chow (Figs 2a and 7b) . Likewise, the difference in glucose tolerance observed between βAMPKdKO and heterozygous mice on normal chow (∼5 mmol/l at 60 min; Fig. 2e ) was substantially reduced when the comparison between genotypes was performed in mice maintained on high-fat diet (∼2 mmol/l at 60 min; Fig. 7c ). By contrast, the enhanced insulin sensitivity of βAMPKdKO mice (∼20% of the initial glucose level 30 min. post insulin injection; Fig. 2 g ) was maintained or enhanced on high-fat diet Glc, glucose; white bars, heterozygous; black bars, βAMPKdKO. h Immunofluorescence staining of GLUT2 expression at the plasma membrane of pancreatic islet beta cells; 15 islets from two pairs of mice of each genotype were analysed. Scale bar, 75 µm. Het, heterozygous. i Granule docking in control (Het) or βAMPKdKO beta cells; 15 cells from four separate islets, two mice per genotype were analysed by transmission electron microscopy. The relative number of morphologically docked granules was calculated by dividing that of docked granules (those within 400 nm of the plasma membrane) by that of total cytosolic granule number and is quantified in bar graph (j), see ESM 1. Scale bar, 2 µm. Data are expressed as means ± SEM; ***p<0.001 (∼30% of initial glucose; Fig. 7d) . Strikingly, the 3.5-fold decrease in glucose-stimulated insulin secretion observed in islets from heterozygous mice maintained on high-fat diet compared with normal chow (from ∼0.7 to 0.2% per 30 min; Figs 6a and 7e) was reduced in βAMPKdKO mouse islets to ∼0.6-fold (from ∼1.3 to 0.8% per 30 min.). Hence, βAMPKdKO mice were still susceptible to the effects of high-fat diet, albeit to a lesser extent than controls.
Overexpression of constitutively active AMPK in beta cells causes glucose intolerance
The above results suggested that, at extrapancreatic sites of RIP2.Cre expression, notably in the mediobasal hypothalamus, AMPK activity is permissive of insulin secretion in vivo.
To determine whether increases in AMPK imposed selectively in beta cells affect insulin secretion in vivo, we generated transgenic mice in which the constitutively active enzyme (AMPK.CA) [6] was expressed under the control of the insulin promoter (Fig. 8a) . Of two founder mouse lines generated (Fig. 8b) , we examined in detail one line carrying two transgene copies. Overexpression of the mRNA was clearly evident in islets (Fig. 8c, d ) and under the control of glucose ex vivo (as expected for expression under the insulin promoter; Fig. 8e ), but barely (<0.001% of the islet level) in the hypothalamus or other tissues (Fig. 8d, f) , reflecting the more restricted expression of the RIP2 transgene to the beta cell in adult mice [44] .
Islets from transgenic mice overexpressing AMPK.CA (AMPK.CA transgenic) displayed a significant increase in total (α1 + α2 complex) AMPK activity at elevated (16.7 mmol/l), but not at low (2.8 mmol/l) glucose concentrations, where the endogenous enzyme was strongly activated (Fig. 8 g, h) [14] . Conversely, AMPK activity was reduced at low glucose concentrations in islets from AMPK.DN transgenic mice, generated in parallel with AMPK.CA mice (Fig. 8g, h) . Assuming approximately equal endogenous AMPK levels in beta compared with islet non-beta cells (ESM Fig. 1 ) and an islet beta cell content of 60% [34] , AMPK activity was increased by 36% and reduced by 50%, in beta cells by overexpression of AMPK. CA or AMPK.DN respectively.
Maintained on normal chow, AMPK.CA and AMPK.DN transgenic mice displayed normal body weight increases (Fig. 9a, b) . Whereas male AMPK.CA transgenic mice displayed abnormal glucose tolerance at 3 (Fig. 9c ), but not 6 (Fig. 9e) months, no abnormalities were seen in AMPK. DN transgenic animals (Fig. 9d, f) or in female AMPK.CA mice (not shown). The abnormalities in AMPK.CA transgenic mice were not associated with any alterations in insulin sensitivity (Fig. 9g, h ), but with decreased fasting Fig. 7 AMPK deletion attenuates the deleterious effects of high-fat feeding on glucose tolerance. a Body weight changes in βAMPKdKO (triangles) and heterozygous (circles) mice over 2 to 18 weeks on high-fat diet (60%). b Blood glucose levels in βAMPKdKO (black bars) and heterozygous (white bars) mice on high-fat diet for 6 weeks with free access to food or fasted for 15 h. c Glucose tolerance after intraperitoneal (IP) glucose injection and (d) whole-body insulin sensitivity after IP insulin injection of βAMPKdKO mice on high-fat diet for 6 weeks. Triangles, βAMPKdKO; circles, heterozygous. e Glucose-stimulated insulin secretion of six size-matched islets from βAMPKdKO and control (Ctrl) mice maintained on high-fat diet for 18 weeks. Islets were statically incubated at 3 mmol/l (white bars) and 16.7 mmol/l (black bars) glucose for 0.5 h. n=3 mice per each genotype. Data are expressed as means ± SEM; *p<0.05, ***p<0.001 and stimulated plasma insulin levels (Fig. 9i, j) and a 25% decrease in beta cell area (0.09±0.02% in wild-type vs 0.068±0.04% in transgenic littermates; data not shown). No significant changes in these variables were observed in AMPK.DN transgenic mice.
To determine whether the alterations in insulin secretion in AMPK.CA mice also result from defects at the level of the beta cell, we performed studies with isolated islets. Insulin release stimulated by 16.7 mmol/l glucose was decreased by >60% (Fig. 9k) , a similar change to that observed after maintenance of mice for 18 weeks on high-fat diet. Indeed, islets from AMPK.CA transgenic mice maintained on highfat diet displayed no further diminution in glucose-stimulated insulin secretion compared with wild-type littermates on the same diet (Fig. 9k) . Conversely, glucose-stimulated insulin release was significantly enhanced in islets from AMPK.DN transgenic mice (Fig. 9l) , reminiscent of the effect of deleting AMPKα1 and -α2 subunits (Fig. 6a) , although in this case the improved secretion was eliminated in islets from animals fed a high-fat diet.
Discussion
The principal aim of this study was to determine the physiological impact of complete and selective loss of both catalytic isoforms of AMPK from pancreatic beta cells. This is an important question, given the likely role of AMPK as a target for glucose-lowering drugs and uncertainties surrounding the role of AMPK in the beta cell [5, 6, 15, 18, 21, 45, 46] .
Cell autonomous roles of AMPK within the beta cell Examined here in isolated islets and beta cells, total inactivation of AMPK led to a potentiation of glucoseinduced insulin secretion. We also noted an increase in ATP-sensitive K + (K ATP ) channel activity at low glucose concentrations (Fig. 4b, c) , perhaps reflecting altered trafficking of channel subunits [47] . However, glucoseinduced K ATP channel closure and increases in intracellular Ca 2+ were unaltered, suggesting that the loss of an inhibitory effect of AMPK-mediated phosphorylation of kinesin light chains [16, 17] and increased granule translocation to the plasma membrane (Fig. 6i, j) may underlie the enhanced secretion. Conversely, selective activation of AMPK in beta cells in βAMPK.CA transgenic mice decreased glucose-stimulated insulin secretion. These findings are consistent with previous results involving the overexpression in islets from of AMPK.CA animals in vitro [21] , as well as with the effects of pharmacological activation of AMPK in clonal beta cells and isolated islets using AICAR or metformin [4, 6, 14, 48] . Furthermore, a diminished number of docked granules was observed in MIN6 cells overexpressing AMPK.CA [16] . We also show here that AMPK deletion leads to a decrease in cell volume, an effect strikingly different from that of deleting the upstream kinase, LKB1. Indeed, beta cells lacking LKB1 as a result of excision mediated either by RIP2.Cre (G. Sun, A. Tarasov, J. McGinty) or pancreas duodenum homeobox-1 promoter/Cre recombinaseoestrogen receptor (PDX-1-CreER) [38, 49] are larger than wild-type beta cells. LKB1 and AMPK appear therefore to engage substantially distinct downstream signalling pathways in beta cells, the former acting at least to a large extent via polarity-regulating kinase partitioning-defective 1/microtubule affinity-regulating kinase 2 (PAR1B/MARK2) [38, 49] .
In the present study, inactivation of AMPK in RIP2.Cre neurons exerted no apparent effect on body mass or food intake. However, αAMPKdKO mice displayed defective glucose homeostasis due to abnormalities in the capacity of a preserved beta cell mass to secrete insulin in response to hyperglycaemia. This deficiency was only partially compensated for by an increase in insulin sensitivity, probably due to increased insulin receptor levels or enhanced downstream signalling in target tissues [50] . Importantly, we used intraperitoneal injection of glucose, rather than oral administration to achieve increases in blood glucose concentration in the absence of a substantial release of incretins including glucagon-like peptide-1. In this way, we sought to compare the effects of an increase in circulating glucose in vivo with changes imposed on isolated islets. Nonetheless, we noted a dramatic decrease in insulin release in βAMPK.dKO mice in vivo, which was not apparent in vitro.
We considered the possibility that decreases in beta cell and islet size contribute to this deficiency in insulin secretion in vivo. However, the absence of impaired insulin release from islets in vitro (in fact, the opposite was Fig. 9 βAMPK.CA transgenic mice display mild glucose intolerance and reduced insulin secretion. a Growth curves of body weights of AMPK.CA mice and (b) AMPK.DN mice aged 6 to 24 weeks old. c Glucose tolerance at 3 months in AMPK.CA and (d) AMPK.DN mice, and (e, f) at 6 months respectively. g Whole-body insulin sensitivity in AMPK.CA and (h) AMPK.DN mice, with (i, j) insulin response of respective 3-month-old mice assessed by intraperitoneal (IP) injection and measurements of glucose in tail vein at the indicated times (see the Methods). White symbols (a-j), βAMPK.CA or βAMPK.DN; black symbols, control. k Glucose-stimulated insulin secretion assessed in islets from βAMPK.CA and (l) βAMPK.DN transgenic mice and their wild-type littermate controls on normal chow or high-fat (60%) diet (under the bar below HFD) for 18 weeks. Male mice aged 12-14 weeks were used; n=8-13 (a-j), n=3-5 (k, l). Data are expressed as means ± SEM; *p<0.05, **p<0.01, ***p<0.001 observed) makes it unlikely that these changes are responsible for the drastically impaired insulin release observed in vivo in βAMPKdKO mice. It seems that the absence of the 'opposite' in vivo phenotype (i.e. improved glucose intolerance) in mice overexpressing activated AMPK under the same promoter (Fig. 9c, e, g, i) is most likely to reflect the predominant expression of the transgene in the pancreatic beta cell (rather than the hypothalamus) in adult mice. One possible explanation for these data is that a signal or signals emanating from RIP2.Cre neurons controls the activity of beta cells in vivo. Indeed, central administration of leptin has previously been shown to inhibit insulin secretion in vivo [51] and it is conceivable that this involves RIP2.Cre neurons and intracellular signalling pathways modulated by AMPK. Nevertheless, further and more definitive studies are needed to ascertain whether and by what means RIP.Cre neurons may influence insulin secretion.
A further interesting finding of the present studies is that mice lacking AMPK in the beta cell are somewhat less susceptible to the deleterious effects of high-fat diet on glucose metabolism and insulin secretion in vitro. These results are consistent with the previously demonstrated role of AMPK [18] in the actions of cytokines [19] on beta cell function and mass.
Conclusions
The results presented here suggest that activation of AMPK in hypothalamic neurons and in pancreatic beta cells play distinct roles in the control of insulin release in vivo. Our findings should inform the use and development of agents that act through AMPK to control glycaemia.
